Cost-effectiveness of abatacept compared to other biological agents for the treatment of moderately to severely active rheumatoid arthritis in patients who failed with methotrexate in Peruvian Social Security during 2010

Descripción del Articulo

Objective: To estimate the cost-effectiveness of Abatacept in combination with Methotrexate (MTX) versus other biologic DMARDs in combination with MTX in patients with moderately to severely active rheumatoid arthritis. Materials and methods: A sequential therapy model was adapted...

Descripción completa

Detalles Bibliográficos
Autores: Becerra Rojas, Felipe, Benites Chacaltana, César, Aiello, Eleonora, Zingoni, Carolina, Bergman, Gert, Drost, Pieter, Sanabria Montañez, César
Formato: artículo
Fecha de Publicación:2024
Institución:Colegio Médico del Perú
Repositorio:Acta Médica Peruana
Lenguaje:español
OAI Identifier:oai:amp.cmp.org.pe:article/1122
Enlace del recurso:https://amp.cmp.org.pe/index.php/AMP/article/view/1122
Nivel de acceso:acceso abierto
Materia:Artritis reumatoide
análisis costo-eficiencia
Rheumatoid arthritis
cost efficiency analysis
id REVCMP_40dc7d2f3930c213c6fdd9a784ce81c8
oai_identifier_str oai:amp.cmp.org.pe:article/1122
network_acronym_str REVCMP
network_name_str Acta Médica Peruana
repository_id_str .
spelling Cost-effectiveness of abatacept compared to other biological agents for the treatment of moderately to severely active rheumatoid arthritis in patients who failed with methotrexate in Peruvian Social Security during 2010Costo efectividad de Abatacept en comparación con otras terapias biológicas para el tratamiento de la artritis reumatoide moderada a severamente activa en pacientes que han fallado al tratamiento con metotrexato en EsSalud para el año 2010Becerra Rojas, Felipe Benites Chacaltana, César Aiello, Eleonora Zingoni, Carolina Bergman, Gert Drost, Pieter Sanabria Montañez, César Artritis reumatoideanálisis costo-eficienciaRheumatoid arthritiscost efficiency analysisObjective: To estimate the cost-effectiveness of Abatacept in combination with Methotrexate (MTX) versus other biologic DMARDs in combination with MTX in patients with moderately to severely active rheumatoid arthritis. Materials and methods: A sequential therapy model was adapted for representing disability using the HAQ Index in a 5-year horizon period for a 1000-patient cohort. Abatacept in combination with MTX was compared against etanercept, rituximab, infliximab, adalimumab, and tocilizumab, all of them combined with MTX. Results: The cost of abatacept therapy was S/. 169 263 and its effectiveness was found to be 1.96 QALY. Compared to etanercept, adalimumab, infliximab and tocilizumab, abatacept has shown to be the most effective agent in terms of QALYs and the least expensive. Compared to rituximab, abatacept has an incremental cost effectiveness ratio of S/. 75 493 per QALY gained. Conclusions: According to this model, abatacept was found to be superior compared to etanercept, adalimumab, infliximab, and tocilizumab, from the Peruvian Social Security (EsSalud) perspective for the treatment of moderately to severely active Rheumatoid Arthritis in patients who failed using a MTX-based therapy.Objetivo: Estimar la costo efectividad de Abatacept combinado con Metotrexato (MTX) en comparación a otras DARMEs biológicas, en combinación con MTX, en pacientes con AR moderada a severamente activa. Materiales y métodos: Se adaptó un modelo de secuencias de tratamiento para la representación de la invalidez en términos del índice HAQ en un horizonte de 5 años de enfermedad para una cohorte de 1 000 pacientes. Abatacept en combinación con MTX se comparó contra etanercept, rituximab, infliximab, adalimumab y tocilizumab, todas asociadas a MTX. Resultados: El costo de tratamiento con Abatacept es de S/. 169 263 y su efectividad es de 1.96 AVAC. Respecto a etanercept, adalimumab, infliximab y tocilizumab, abatacept se ha mostrado más efectivo en términos de AVACs y menos costoso. Respecto a rituximab, abatacept presenta un índice de costo efectividad incremental de S/ 75 493 por AVAC ganado. Conclusiones: Abatacept es dominante frente a Etanercept, Adalimumab, Infliximab y Tocilizumab, desde la perspectiva del Seguro Social de Salud (EsSalud) para el tratamiento de pacientes con AR moderada a severamente activa que han fallado a MTX.Colegio Médico del Perú2024-05-20info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://amp.cmp.org.pe/index.php/AMP/article/view/1122ACTA MEDICA PERUANA; Vol. 28 No. 4 (2011); 200-210ACTA MEDICA PERUANA; Vol. 28 Núm. 4 (2011); 200-2101728-59171018-8800reponame:Acta Médica Peruanainstname:Colegio Médico del Perúinstacron:CMPspahttps://amp.cmp.org.pe/index.php/AMP/article/view/1122/597Copyright (c) 2020 ACTA MEDICA PERUANAinfo:eu-repo/semantics/openAccessoai:amp.cmp.org.pe:article/11222024-05-21T07:18:11Z
dc.title.none.fl_str_mv Cost-effectiveness of abatacept compared to other biological agents for the treatment of moderately to severely active rheumatoid arthritis in patients who failed with methotrexate in Peruvian Social Security during 2010
Costo efectividad de Abatacept en comparación con otras terapias biológicas para el tratamiento de la artritis reumatoide moderada a severamente activa en pacientes que han fallado al tratamiento con metotrexato en EsSalud para el año 2010
title Cost-effectiveness of abatacept compared to other biological agents for the treatment of moderately to severely active rheumatoid arthritis in patients who failed with methotrexate in Peruvian Social Security during 2010
spellingShingle Cost-effectiveness of abatacept compared to other biological agents for the treatment of moderately to severely active rheumatoid arthritis in patients who failed with methotrexate in Peruvian Social Security during 2010
Becerra Rojas, Felipe
Artritis reumatoide
análisis costo-eficiencia
Rheumatoid arthritis
cost efficiency analysis
title_short Cost-effectiveness of abatacept compared to other biological agents for the treatment of moderately to severely active rheumatoid arthritis in patients who failed with methotrexate in Peruvian Social Security during 2010
title_full Cost-effectiveness of abatacept compared to other biological agents for the treatment of moderately to severely active rheumatoid arthritis in patients who failed with methotrexate in Peruvian Social Security during 2010
title_fullStr Cost-effectiveness of abatacept compared to other biological agents for the treatment of moderately to severely active rheumatoid arthritis in patients who failed with methotrexate in Peruvian Social Security during 2010
title_full_unstemmed Cost-effectiveness of abatacept compared to other biological agents for the treatment of moderately to severely active rheumatoid arthritis in patients who failed with methotrexate in Peruvian Social Security during 2010
title_sort Cost-effectiveness of abatacept compared to other biological agents for the treatment of moderately to severely active rheumatoid arthritis in patients who failed with methotrexate in Peruvian Social Security during 2010
dc.creator.none.fl_str_mv Becerra Rojas, Felipe
Benites Chacaltana, César
Aiello, Eleonora
Zingoni, Carolina
Bergman, Gert
Drost, Pieter
Sanabria Montañez, César
author Becerra Rojas, Felipe
author_facet Becerra Rojas, Felipe
Benites Chacaltana, César
Aiello, Eleonora
Zingoni, Carolina
Bergman, Gert
Drost, Pieter
Sanabria Montañez, César
author_role author
author2 Benites Chacaltana, César
Aiello, Eleonora
Zingoni, Carolina
Bergman, Gert
Drost, Pieter
Sanabria Montañez, César
author2_role author
author
author
author
author
author
dc.subject.none.fl_str_mv Artritis reumatoide
análisis costo-eficiencia
Rheumatoid arthritis
cost efficiency analysis
topic Artritis reumatoide
análisis costo-eficiencia
Rheumatoid arthritis
cost efficiency analysis
description Objective: To estimate the cost-effectiveness of Abatacept in combination with Methotrexate (MTX) versus other biologic DMARDs in combination with MTX in patients with moderately to severely active rheumatoid arthritis. Materials and methods: A sequential therapy model was adapted for representing disability using the HAQ Index in a 5-year horizon period for a 1000-patient cohort. Abatacept in combination with MTX was compared against etanercept, rituximab, infliximab, adalimumab, and tocilizumab, all of them combined with MTX. Results: The cost of abatacept therapy was S/. 169 263 and its effectiveness was found to be 1.96 QALY. Compared to etanercept, adalimumab, infliximab and tocilizumab, abatacept has shown to be the most effective agent in terms of QALYs and the least expensive. Compared to rituximab, abatacept has an incremental cost effectiveness ratio of S/. 75 493 per QALY gained. Conclusions: According to this model, abatacept was found to be superior compared to etanercept, adalimumab, infliximab, and tocilizumab, from the Peruvian Social Security (EsSalud) perspective for the treatment of moderately to severely active Rheumatoid Arthritis in patients who failed using a MTX-based therapy.
publishDate 2024
dc.date.none.fl_str_mv 2024-05-20
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://amp.cmp.org.pe/index.php/AMP/article/view/1122
url https://amp.cmp.org.pe/index.php/AMP/article/view/1122
dc.language.none.fl_str_mv spa
language spa
dc.relation.none.fl_str_mv https://amp.cmp.org.pe/index.php/AMP/article/view/1122/597
dc.rights.none.fl_str_mv Copyright (c) 2020 ACTA MEDICA PERUANA
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2020 ACTA MEDICA PERUANA
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Colegio Médico del Perú
publisher.none.fl_str_mv Colegio Médico del Perú
dc.source.none.fl_str_mv ACTA MEDICA PERUANA; Vol. 28 No. 4 (2011); 200-210
ACTA MEDICA PERUANA; Vol. 28 Núm. 4 (2011); 200-210
1728-5917
1018-8800
reponame:Acta Médica Peruana
instname:Colegio Médico del Perú
instacron:CMP
instname_str Colegio Médico del Perú
instacron_str CMP
institution CMP
reponame_str Acta Médica Peruana
collection Acta Médica Peruana
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1842710603140956160
score 12.851315
Cost-effectiveness of abatacept compared to other biological agents for the treatment of moderately to severely active rheumatoid arthritis in patients who failed with methotrexate in Peruvian Social Security during 2010
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).

Ejemplares Similares